Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05926765Phase 2Recruiting

A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

Role: lead

NCT06544798Phase 2Enrolling By Invitation

Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia

Role: lead

NCT02446249Phase 1Active Not Recruiting

Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction

Role: lead

NCT05603312Phase 1Completed

A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants

Role: lead

NCT05894343Phase 1Active Not Recruiting

Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease

Role: lead

NCT05060341Active Not Recruiting

Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia

Role: lead

All 6 trials loaded